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PHARMACY DISPENSING PATTERNS,
COST AND HEALTHCARE UTILIZATION:
A STUDY OF LANSOPRAZOLE
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Houston,TX, USA
In the Department of Veterans Affairs (VA) expenditures
for pharmaceuticals were nearly $2Billion or 11% of 
the total budget in FY1999 (October 1998–September
1999), and have been increasing from 11 to 21 percent
annually.
OBJECTIVE: To develop methods to examine pharmacy
dispensing patterns and to determine the association with
healthcare costs and utilization.
METHODS: 24,765 patients who received a prescription
of Lansoprazole during FY1999 at any of the 10 hospi-
tals one regional network were studied. Dispensing pat-
terns leading to overlaps (overﬁlling) and gaps (underuse),
deﬁned as a dispensing at least 10 days before or after,
respectively, the days supply of the prior dispensing
ended, were identiﬁed. Outpatient visit and hospitaliza-
tion rates were calculated for 6 months of follow-up and
tested for associations with overﬁlling and underuse.
Source of dispensing, Mail (M) or Window (W), and days
of supply were examined to gain insight into factors that
contribute to inefﬁcient dispensing patterns.
RESULTS: 49.7% of all patients experienced an overlap,
51.1% experienced a gap, and 27.2% experienced both.
The net cost associated with overﬁlling for 6 months of
follow-up was $392,616, or 7.9% of the total 6-month
cost of approximately $5Million for Lansoprazole. Gaps
and overlaps in medications were associated with higher
utilization of both inpatient and outpatient services. A
mix of MW dispensing pairs more often resulted in gaps
or overlaps than concordant pairs (MM or WW). 10.7%
of dispensings were for days supply of 31-to-90 days;
however, 49.2% of 31-to-90 day prescriptions resulted in
overlaps.
CONCLUSION: Overﬁlling is estimated to be 8% of total
costs for Lansoprazole, and is associated with increased
utilization. Further research is needed to determine how
pharmacy dispensing patterns impact healthcare costs and
outcomes. With increasing pharmaceutical costs and
emphasis on patient safety, research into efﬁcient delivery
and timely receipt of medication is important.
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OBJECTIVES: The purpose of this study is to evaluate
the effect of rabeprazole (RAB) 20mg daily on HRQoL
among patients that participated in the Future of Acid
Suppression Therapy (F.A.S.T.) trial. The F.A.S.T. trial
was an open-label, multicenter, 8-week study measuring
the effectiveness of RAB in 2579 patients with erosive
gastroesophageal reﬂux disease (GERD). The two sub-
populations in this analysis were patients reporting 
prior ineffective relief with omeprazole (OME) (n = 290)
or lansoprazole (LAN) (n = 212) within 3 months of study
entry.
METHODS: The SF-36 health survey was used to
measure HRQoL in patients at baseline and after 8 weeks
of treatment with RAB. The SF-36 includes eight scales:
Physical Functioning (PF), Role-Physical (RP), Bodily
Pain (BP), General Health (GH), Vitality (VT), Social
Functioning (SF), Role-Emotional (RE) and Mental
Health (MH). Two summary measures, Physical Health
Component Summary (PCS) and Mental Health Compo-
nent Summary (MCS), are produced from aggregating the
most highly related scales. This study used paired t-tests
to compare baseline to 8-week scores for signiﬁcant
changes in HRQoL.
RESULTS: There were 248 OME and 180 LAN patients
that completed a SF-36 survey at baseline and 8-weeks.
All scales and summary scores in both groups had a sta-
tistically signiﬁcant (p < 0.05) mean increase after 8 weeks
of treatment on RAB except for PF in patients having
prior ineffective OME therapy. For both groups, the fol-
lowing scales had a increase in score of greater than ﬁve
points from baseline to 8-weeks which is considered clin-
ically signiﬁcant: RP, BP, VT, SF, and RE. In addition the
group of patients having prior ineffective OME therapy
also had a clinically signiﬁcant increase in MH.
CONCLUSIONS: Overall, RAB showed signiﬁcant
improvements in HRQoL among patients with erosive
GERD who reported ineffective relief with prior OME or
LAN therapy.
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OBJECTIVES: The GERD Symptom Assessment Scale
(GSAS) measures distress associated with 15 GERD-
related symptoms. The purpose of this study was to 
evaluate its factor structure.
METHODS: The GSAS was collected at baseline and four
weeks following treatment in two randomized, placebo-
controlled trials of rabeprazole for moderately severe
GERD. Patients rated how distressed they were by each
symptom from 0 (no symptom or not at all distressed) to
